Seeking Alpha

Chris DeMuth Jr.'s  Instablog

Chris DeMuth Jr.
Send Message
"It's not given to human beings to have such talent that they can just know everything about everything all the time. But it is given to human beings who work hard at it - who look and sift the world for a misplaced bet - that they can occasionally find one." - Charlie Munger I look... More
My blog:
Rangeley Capital on Harvest
My book:
Rangeley Capital Best Investment Ideas
  • Regulatory Sclerosis 0 comments
    Jan 17, 2014 1:26 PM | about stocks: GCVRZ, SNY

    Time is short.

    I hope that you might be interested in this article regarding the FDA's review of an innovative MS therapy. The appeal is at a critical stage that could be influenced by the views of MS doctors and patients. If you have a view on this article - favorable or unfavorable - or on whether or not Lemtrada should be one option for MS doctors treating their patients, then please consider writing a letter to the editor.

    wsj.ltrs@wsj.com

    Mr. Timothy Lemmer

    Letters Editor, The Wall Street Journal

    1211 Avenue of the Americas

    New York, NY 10036

    There is a 300 word limit. Please include the date (Friday, January 17, 2013), headline (The FDA Nixes a Pathbreaking Drug for MS) and page number of article (A13), as well as your name and the city where you are located.

    One important attribute of the FDA's review was the total exclusion of MS experts from their decision-making process. So, now could be a useful time for experts to speak up. For something to think about, here are some recent quotes from three such experts.

    Disclosure: I am long GCVRZ.

    Additional disclosure: Chris DeMuth Jr is a portfolio manager at Rangeley Capital, a partnership that invests with a margin of safety by buying securities at deep discounts to their intrinsic value and unlocking that value through corporate events. In order to maximize total returns for our partners, we reserve the right to make investment decisions regarding any security without further notification except where such notification is required by law. Image by David G Klein; more of his art available here: www.illoz.com/kleinart/

    Themes: Lemtrada, Sanofi, Genzyme, alemtuzumab, FDA Stocks: GCVRZ, SNY
Back To Chris DeMuth Jr.'s Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »

Latest Comments


Most Commented
  1. GCVRZ Forum Archive (1,000 Comments)
  2. Event Driven Q&A Forum (224 Comments)
  3. GCVRZ Forum (159 Comments)
  4. GPT Forum (127 Comments)
  5. Shorts Forum (120 Comments)
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.